Ibandronic acid

Phase 3Small molecule

Roche

Ibandronic acid is one of 82 small molecule programs targeting Postmenopausal Osteoporosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postmenopausal OsteoporosisActive, not recruiting

Breast CancerActive, not recruiting

OsteoporosisActive, not recruiting

Postmenopausal OsteoporosisPreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

OsteoporosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ibandronic acid

Roche

Phase 3

1 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

MS Contin

Merck & Co.

Preclinical

2 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Spravato

WWim Janssens

Preclinical

2 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis

Completed·CClinic of Endocrinology and Metabolic Disorders, Macedonia··NCT02271204·700 enrolled

Breast Cancer1 trial

Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients

Unknown status·UUniversity of Turku·Phase 2·NCT00381368·60 enrolled

Osteoporosis1 trial

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis

Completed· Roche logo

Roche·Phase 3·NCT00447915·1,265 enrolled

Adjuvant1 trial

Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors

Completed·—·Phase 2·NCT02616744·171 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ibandronic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibandronic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibandronic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Ibandronic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Breast Cancer1 trial

Osteoporosis1 trial

Adjuvant1 trial

References

Drug Info

Quick Facts

Related News